Lonza grows strongly after takeover and increases goals – News – News

In addition,

Lonza grows strongly after takeover:

  • Lonza has returned to growth mode. In addition,
  • Not least thanks to the purchase of a large production system from Roche in California. Similarly, the pharmaceutical supplier has increased significantly thanks to the purchase of a large production system. Moreover,
  • Now the company is a little more dares to do. For example,

Lonza’s turnover increased by 17 percent from January to June 2025 to CHF 3,58 billion, the company announced.

In the previous year, Lonza had troubled the elimination of the large Moderna lonza grows strongly after takeover order for Corona vaccination. However, A large production facility that was bought last autumn Roche has now driven the turnover significantly.

Half a billion from California – Lonza grows strongly after takeover

The work in the California Vacaville should contribute around half a billion francs to group sales in 2025. However, explained CFO Philippe Deecke. Consequently, Customers’ interest in the new facility is still great, at the same time it delivers a better margin than expected.

Legend: Lonza’s sales increased in the first half of the year. The company is now slightly increasing the outlook for the year as a whole. KEYSTONE/Gaetan Bally

The operating profit («Core-Ebitda») subsequently rose even more than the sales with plus 18.6 percent to CHF 1,06 billion. The margin increased from 29.2 to 29.6 percent. At the end of the success of the success. CHF 426 million was as a net profit, after 330 million in the previous year. Analysts had expected deeper values.

Slightly higher forecast

In view of the good development in the first half of the year. Lonza easily increases the view for the year in the CDMo business. The group is now promising sales growth in local currencies of 20 to 21 percent, before that “almost” 20 percent were promised.

Capsule business stabilizes

Box open Box zuklappen lonza grows strongly after takeover

The capsule. nutritional supplement business meanwhile maintained sales of CHF 523 million and thus stood for almost 15 percent of the group sales. Management should not be inconvenient to stabilize sales. as one wants to separate from the area due to the lack of synergies.

Because the capsule business shrank for a long time and casts less profit than the other Lonza divisions. In numbers: In the first half of 2025, the “Capsules & Health Ingredient” area came to an operational margin of 26.2 percent, the three CDMO areas together to 30.2 percent.

Investors grab Wacker on the stock exchange: around 10.50 a.m., the Lonza papers are more expensive to CHF 581. With an increase of about 7 percent since January, the shares have been making something in this year’s SMI winner list.

Further reading: 7-Day Weather Forecast for Jefferson CountyRescuers to recover wreckage of sunken ferry near BaliLake Oszi Osborne, leader and vocalist of the Black Sabbath group diedWhy Expensive Labubus Could Become Sound InvestmentsWynau: Destroyed farmhouse by fire.

Comments (0)
Add Comment